The effect of griseofulvin on human spermatogenesis has been investigated in two groups of persons for periods ranging from three to six months at a daily intake level of 2 gm. These men, in normal health, were confined in two separate institutions, and each group was living under the same conditions of diet and exercise. The first group of 14 men (Table 1) was in the age group of 23-47 years (mean age 33), the second, of 12 persons, ranged in age from 20 to 45 years with a mean age of 31.
The same investigative protocol was followed in both groups. Testicular biopsies were obtained during a short control period in which two semen specimens were examined to establish the level of semen quality prior to therapy. Thereafter, in the first group, the griseofulvin was taken orally (2 gm. daily) for three months, and in the second group, the
Mac LEOD J, NELSON WO. Griseofulvin and Human Spermatogenesis. AMA Arch Derm. 1960;81(5):758–759. doi:10.1001/archderm.1960.03730050114019
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: